Session » Metabolic & Crystal Arthropathies Poster I: Clinical

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 330

Acute Gout Attacks Among Patients Admitted Due to Heart Failure: Analysis of NIS Database

9:00AM-11:00AM: Abstract Number: 328

Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events

9:00AM-11:00AM: Abstract Number: 353

Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study

9:00AM-11:00AM: Abstract Number: 333

Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients

9:00AM-11:00AM: Abstract Number: 345

Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey

9:00AM-11:00AM: Abstract Number: 364

Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series

9:00AM-11:00AM: Abstract Number: 349

Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study

9:00AM-11:00AM: Abstract Number: 365

Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 360

Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis

9:00AM-11:00AM: Abstract Number: 355

Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol

9:00AM-11:00AM: Abstract Number: 339

Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate

9:00AM-11:00AM: Abstract Number: 341

Development of a Multivariable Improvement Measure for Gout

9:00AM-11:00AM: Abstract Number: 338

Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults

9:00AM-11:00AM: Abstract Number: 363

Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout

9:00AM-11:00AM: Abstract Number: 358

Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients

9:00AM-11:00AM: Abstract Number: 343

Emergency Department Length of Stay in Patients with Acute Gout

9:00AM-11:00AM: Abstract Number: 354

Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis

9:00AM-11:00AM: Abstract Number: 329

Excessive Alcohol Intake Is Associated with Tophi Formation in Gout Patients

9:00AM-11:00AM: Abstract Number: 344

Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 361

Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares

9:00AM-11:00AM: Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study

9:00AM-11:00AM: Abstract Number: 337

Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study

9:00AM-11:00AM: Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis

9:00AM-11:00AM: Abstract Number: 359

Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge

9:00AM-11:00AM: Abstract Number: 332

Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis

9:00AM-11:00AM: Abstract Number: 340

Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels

9:00AM-11:00AM: Abstract Number: 357

Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification

9:00AM-11:00AM: Abstract Number: 362

Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries

9:00AM-11:00AM: Abstract Number: 347

Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease

9:00AM-11:00AM: Abstract Number: 348

Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry

9:00AM-11:00AM: Abstract Number: 352

Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 350

Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events

9:00AM-11:00AM: Abstract Number: 335

Renal Transplant Complications in Patients with and Without Gout

9:00AM-11:00AM: Abstract Number: 342

Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout

9:00AM-11:00AM: Abstract Number: 351

Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City

9:00AM-11:00AM: Abstract Number: 366

Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 346

Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016

9:00AM-11:00AM: Abstract Number: 334

The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout

9:00AM-11:00AM: Abstract Number: 336

Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].